April 13, 2015 — Patients who use Onglyza to treat type-2 diabetes may be significantly more likely to develop heart failure and more likely to die, according to an FDA analysis of clinical trial data.
The data came from the SAVOR clinical trial, which involved about 16,500 diabetic patients who had a high risk of cardiovascular disease. The patients were given either Onglyza or a placebo.
Now, the FDA is warning that Onglyza may also increase the risk of “all cause mortality,” whether they developed heart problems or not.
The FDA did not determine why Onglyza might increase the risk of death. They asked an expert committee for their opinions, given the fact that “a large number of deaths were observed.”
Bloomberg talked to experts who said conclusions might be difficult because the patients in the study were already older, sicker, with diabetes and pre-existing cardiovascular risk-factors.
Onglyza belongs to a new class of diabetes drugs that work by inhibiting DPP-4, which helps the body control blood-sugar levels by increasing insulin production. The FDA is also investigating whether this mechanism of action might increase the risk of pancreatitis (pancreas inflammation) and pancreatic cancer.
Do I have an Onglyza Lawsuit?
The Schmidt Firm, PLLC is currently accepting Onglyza induced injury cases in all 50 states. If you or somebody you know has been diagnosed with a pancreatic cancer or a serious side effect, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.